Researcher Profile

Researcher Profile

Patrick Chi-Chung Ma, MD, MSc

Patrick Chi-Chung Ma, MD, MSc

Professor, Department of Medicine
Division of Hematology and Oncology
Scientific Program:Next-Generation Therapies

Research Interests

  • Therapeutics
  • Neoplasms
  • Non-Small Cell Lung Carcinoma
  • Lung Neoplasms
  • Mutation
  • Small Cell Lung Carcinoma
  • ErbB Receptors
  • Hepatocyte Growth Factor
  • Neoplasm Metastasis
  • Protein-Tyrosine Kinases
  • Adenocarcinoma of Lung
  • Erlotinib Hydrochloride

Clinical Trials

APG-115 - A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors
Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medically Inoperable Stages I or IIA Non Small Cell Lung Cancer (NSCLC)(KEYNOTE-867) MK 3475-867
A Phase III Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib, Compared to Concurrent Chemoradiation Therapy Followed by Placebo in Participants with Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK7339-013)
A Phase I/II Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C mutation (MRT849-001)
Phase II, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer
S1827 A randomized Phase III trial comparing prophylactic cranial irradiation (PCI) for any patient with small cell lung cancer (either extensive or limited stage) to active surveillance with MRI in place of PCI
CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors
A Phase II Study of Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select IIIA [T3N1, T4N0-1] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA) Big Ten Cancer Research Consortium BTCRC-LUN19-396
NRG-LU007 Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial
DuRvalumab MEDI4730 with chEmotherapy as first line treAtment in advanced pleural Mesothelioma A phase 3 Randomised trial (DREAM3R)
Phase Ib Study of Brigatinib Plus Bevacizumab in Patients with ALK- rearranged Non-Small Cell Lung Cancer (NSCLC) Who Have Previously Progressed on Prior ALK-Directed Therapy
Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

Recent Publications


Shen, C, Holguin, RAP, Schaefer, E, Zhou, S, Belani, CP, Ma, PC & Reed, MF 2022, 'Utilization and costs of epidermal growth factor receptor mutation testing and targeted therapy in Medicare patients with metastatic lung adenocarcinoma', BMC health services research, vol. 22, no. 1, 470.


Mattes, MD, Eubank, TD, Almubarak, M, Wen, S, Marano, GD, Jacobson, GM & Ma, PC 2021, 'A Prospective Trial Evaluating the Safety and Systemic Response From the Concurrent Use of Radiation Therapy with Checkpoint Inhibitor Immunotherapy in Metastatic Non–Small Cell Lung Cancer', Clinical Lung Cancer, vol. 22, no. 4, pp. 268-273.
Ma, PC 2021, 'ADAURA: The role of adjuvant EGFR TKI and future consideration (Pro)', Precision Cancer Medicine, vol. 4, no. March, 6.
Khan, SA, Sun, Z, Dahlberg, S, Malhotra, J, Keresztes, R, Ikpeazu, C, Ma, P, Ramalingam, SS & Pillai, R 2021, 'Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504)', JTO Clinical and Research Reports, vol. 2, no. 5, 100166.
He, Y, Chen, L, Zhao, L, Dang, S, Liu, G, Sasada, S, Ma, PC, Zandwijk, NV, Rosell, R, Popper, HH, Wang, H, Jiang, M, Guo, H, Liu, X, Chen, S, Zhang, X, Xu, M, Zhu, B, Liu, M & Zhou, C 2021, 'Genomic and transcriptional alterations in first-line chemotherapy exert a potentially unfavorable influence on subsequent immunotherapy in NSCLC', Theranostics, vol. 11, no. 14, pp. 7092-7109.
Albandar, HJ, Fuqua, J, Albandar, JM, Safi, S, Merrill, SA & Ma, PC 2021, 'Immune-related adverse events (Irae) in cancer immune checkpoint inhibitors (ici) and survival outcomes correlation: To rechallenge or not?', Cancers, vol. 13, no. 5, 989, pp. 1-15.
Nagasaka, M, Asad, MFB, Al Hallak, MN, Uddin, MH, Sukari, A, Baca, Y, Xiu, J, Magee, D, Mamdani, H, Uprety, D, Kim, C, Xia, B, Liu, SV, Nieva, JJ, Lopes, G, Bepler, G, Borghaei, H, Demeure, MJ, Raez, LE, Ma, PC, Puri, S, Korn, WM & Azmi, AS 2021, 'Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC)', Lung Cancer, vol. 160, pp. 92-98.
Lee, M, Jain, P, Wang, F, Ma, PC, Borczuk, A & Halmos, B 2021, 'MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies', Expert Opinion on Therapeutic Targets, vol. 25, no. 4, pp. 249-268.


Attia, CG, Fei, N, Almubarak, M, Ma, PC & Mattes, MD 2020, 'Patterns of disease progression to checkpoint inhibitor immunotherapy in patients with stage IV non-small cell lung cancer', Journal of Medical Imaging and Radiation Oncology, vol. 64, no. 6, pp. 866-872.
Brownmiller, T, Juric, JA, Ivey, AD, Harvey, BM, Westemeier, ES, Winters, MT, Stevens, AM, Stanley, AN, Hayes, KE, Sprowls, SA, Gatesman Ammer, AS, Walker, M, Bey, EA, Wu, X, Lim, ZF, Zhu, L, Wen, S, Hu, G, Ma, PC & Martinez, I 2020, 'Y chromosome LncRNA are involved in radiation response of male non-small cell lung cancer cells', Cancer Research, vol. 80, no. 19, pp. 4046-4057.


Ma, PC 2019, '(Not giving up) the marathon race of Met targeting therapy: Are we there yet?', Clinical Cancer Research, vol. 25, no. 8, pp. 2375-2378.
Jonna, S, Feldman, RA, Swensen, J, Gatalica, Z, Korn, WM, Borghaei, H, Ma, PC, Nieva, JJ, Spira, AI, Vanderwalde, AM, Wozniak, AJ, Kim, ES & Liu, SV 2019, 'Detection of NRG1 gene fusions in solid tumors', Clinical Cancer Research, vol. 25, no. 16, pp. 4966-4972.
Lim, ZF & Ma, PC 2019, 'Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy', Journal of Hematology and Oncology, vol. 12, no. 1, 134.
Chen, R, Xia, W, Wang, S, Xu, Y, Ma, Z, Xu, W, Zhang, E, Wang, J, Fang, T, Zhang, Q, Dong, G, Cho, WCS, Ma, PC, Brandi, G, Tavolari, S, Ujhazy, P, Metro, G, Popper, HH, Yin, R, Qiu, M & Xu, L 2019, 'Long Noncoding RNA SBF2-AS1 Is Critical for Tumorigenesis of Early-Stage Lung Adenocarcinoma', Molecular Therapy - Nucleic Acids, vol. 16, pp. 543-553.
Wu, X, Zhu, L & Ma, PC 2019, NTRK-Targeted Therapy in Lung Cancer. in Current Cancer Research. Current Cancer Research, Springer Nature, pp. 137-161.
Ahmad, Z, Stanazai, Q, Wright, S, Smolkin, M & Ma, PC 2019, 'Primary pleural epithelioid sarcoma of the proximal type: A diagnostic and therapeutic challenge', Translational Lung Cancer Research, vol. 8, no. 5, pp. 700-705.
Morgensztern, D, Rose, M, Waqar, SN, Morris, J, Ma, PC, Reid, T, Brzezniak, CE, Zeman, KG, Padmanabhan, A, Hirth, JA, I. Spira, A, Trepel, JB & Padda, SK 2019, 'RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer', British Journal of Cancer, vol. 121, no. 3, pp. 211-217.
Kibirova, A, Mattes, MD, Smolkin, M & Ma, PC 2019, 'The Journey of an EGFR-Mutant Lung Adenocarcinoma through Erlotinib, Osimertinib and ABCP Immunotherapy Regimens: Sensitivity and Resistance', Case Reports in Oncology, vol. 12, no. 3, pp. 765-776.


Drilon, A, Laetsch, TW, Kummar, S, Dubois, SG, Lassen, UN, Demetri, GD, Nathenson, M, Doebele, RC, Farago, AF, Pappo, AS, Turpin, B, Dowlati, A, Brose, MS, Mascarenhas, L, Federman, N, Berlin, J, El-Deiry, WS, Baik, C, Deeken, J, Boni, V, Nagasubramanian, R, Taylor, M, Rudzinski, ER, Meric-Bernstam, F, Sohal, DPS, Ma, PC, Raez, LE, Hechtman, JF, Benayed, R, Ladanyi, M, Tuch, BB, Ebata, K, Cruickshank, S, Ku, NC, Cox, MC, Hawkins, DS, Hong, DS & Hyman, DM 2018, 'Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children', New England Journal of Medicine, vol. 378, no. 8, pp. 731-739.
Oronsky, B, Ma, P, Reid, TR, Cabrales, P, Lybeck, M, Oronsky, A, Oronsky, N & Carter, CA 2018, 'Navigating the “No Man's Land” of TKI-Failed EGFR-Mutated Non–Small Cell Lung Cancer (NSCLC): A Review', Neoplasia (United States), vol. 20, no. 1, pp. 92-98.
Wu, X, Zhu, L & Ma, PC 2018, 'Next-Generation Novel Noninvasive Cancer Molecular Diagnostics Platforms Beyond Tissues', American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, no. 38, pp. 964-977.

Clinical Trials Search

Children (age < 18 years)
Adults (age >= 18 years)